Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a/1b first-in-human study of oral dubermatinib (TP-0903) in advanced solid tumors
jRCT2080224717Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of dubermatinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 2 more, sponsored by Sumitomo Pharma. Primary endpoints: Safety and tolerability of TP-0903 (dubermatinib), Pharmacokinetics of TP-0903 (dubermatinib) and 1 more. Started Jun 2019; status: completed.
02
Drugs
dubermatinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)ovarian cancermelanoma
Beyond the preview
Go deeper on jRCT2080224717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224717.